Learn more about Bexion Pharmaceuticals through our highlights video

Watch the video


Bexion Pharmaceuticals President & CEO Ray Takigiku featured on ADVANCEMENTS TV with Ted Danson

In this episode, Advancements will explore how lysosomes play a role in a broad range of diseases including cancer, Alzheimer’s, Parkinson’s, and even infectious diseases such as viruses and bacteria. Hearing from experts in the field, audiences will discover how Bexion Pharmaceuticals, Inc. (Bexion) – a clinical stage biotech company– is leveraging the lysosome’s role to treat even very advanced cancers and improve patient’s quality of life.


Dr. Richard Curry, III Medical Director at CTI and Medical Affairs Advisory at Bexion Pharmaceuticals, Inc. recently presented at the 3rd Annual Glioblastoma Drug Development Summit.

Innovation Express magazine cover

Bexion in Innovation Express

Innovation Express is a multi-media healthcare news hub designed to share all Innovation Healthcare Institute (IHCI) events and programs and announce the most innovative items in healthcare. Bexion Pharmaceuticals, Inc. was recently featured in Innovations Express. Please click on the link below to read the article and learn more about our organization.

Read more

– Our Platform

An innovative, targeted approach to treating cancer

For the last 20 years since the mapping of the human genome, many cancer therapeutics have targeted cellular mutations and not the cancer cells’ environment.

By utilizing a small lysosomal protein known as Saposin C our approach specifically targets unique features of cancer cells and their environment, including externalized phosphatidylserine and tumor cell lysosomes.

Learn More

– Our Pipeline

A Pipeline-in-a-Product asset with potential for multiple indications

BXQ-350 is the foundation of our pipeline. Early clinical results have shown a strong safety and tolerability profile.

Learn More

– clinical trials


Our clinical trials are regulated by the Food and Drug Administration (FDA) in the United States and by similar regulatory agencies worldwide.

Learn More


Bexion Resources


Learn More
View All Resources


    Bexion Pharmaceuticals, Inc. Announces First Patient Dosed with BXQ-350 in the RETRO Clinical Study

    October 18, 2022

    Study Aims to Assess Potential for BXQ-350 to Reduce the Intensity and/or Duration of Chemotherapy-Induced Peripheral Neuropathy (CIPN), a Prevalent Limitation of Existing Chemotherapies FOR IMMEDIATE RELEASE Covington, KY, October 18, 2022 Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing biologics for the treatment of cancer and neuropathy, announced today that the first adult patient ... Read More

      Press Release

      Bexion Pharmaceuticals, Inc. to Present at the 2022 European Association of Neuro-Oncology (EANO 2022)

      September 14, 2022

      FOR IMMEDIATE RELEASE [Covington, KY--- 14 September 2022] Bexion Pharmaceuticals, Inc., a mid-stage clinical biopharmaceutical company developing a new generation of biologic immunotherapy to treat solid tumor cancers and Chemotherapy Induced Peripheral Neuropathy (CIPN), announced today that an abstract submitted for an in-person session at the EANO annual meeting to be held in Vienna, Austria ... Read More

      View All Media